Analyst Price Target is $9.00
▲ +57.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lucira Health in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 57.07% upside from the last price of $5.73.
Current Consensus is
The current consensus among 3 investment analysts is to hold stock in Lucira Health.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.